News
Model of Risk of Bleeding Associated with Physical Activity in Hemophiliacs with Factor and Non-Factor Treatment
In the treatment of hemophilia A, both FVIII concentrate replacement therapy and non-factor therapy are available today. However, there is no clinical data comparing the risk of bleeding associated with physical activity between factor and non-factor treatments. In this situation, one approach is to model possible scenarios and attempt to indirectly compare different modalities of bleeding prevention.
When to Consider Gaucher Disease and How to Diagnose It Early and Correctly
Considering Gaucher disease (GD) as a cause of a patient's problems, especially in the case of…
COMMENTARY FROM PRACTICE: On Some Aspects of Care for Patients with Parkinson's Disease
What issues do we still encounter in the diagnosis and treatment of Parkinson's disease even today,...
Detection of ceftazidime/avibactam-resistant Enterobacteriaceae strains using a new rapid test
Ceftazidime/avibactam (CZA) is a relatively new antibiotic with very good efficacy against…
Diagnosing Myelodysplastic Syndrome According to MDS Europe
In 2021, the European Hematology Association (EHA) endorsed the recommendations of the MDS Europe…
Proton Therapy and Its Results in the Treatment of Bilateral Breast Cancer
Breast cancer is the most common malignant tumor disease in women, and its incidence sharply…
Compression Therapy with Zinc Oxide Dressings in Dermatology
Zinc oxide dressings have a long-standing tradition and continue to find their place in modern…
Metamizole in Pain Management for Patients with Subarachnoid Hemorrhage
A study by Czech authors from the University Hospital St. Anna in Brno, recently published in the …
Comparison of the Effectiveness of Different Types of Toothbrushes in Orthodontic Patients
The aim of the study cited below was to evaluate the efficiency of a manual orthodontic brush, an…
Efficacy and Safety of Ozanimod in the Treatment of Relapsing-Remitting MS
The sphingosine-1-phosphate receptor (S1PR) modulator ozanimod has recently been approved for the…